Valneva Confirms Leadership Changes at Annual General Meeting

Valneva SE, a specialty vaccine company, held its Annual General Meeting in Lyon, France. During the meeting, shareholders approved all recommended resolutions, including the 2025 financial statements and measures regarding the company's share capital. The company will relocate its registered office to Lyon following the closure of its Nantes site.

Key appointments were made, with Dr. Gerd Zettlmeissl being named as the new Chair of the Board of Directors, succeeding Anne-Marie Graffin. Zettlmeissl brings over 40 years of experience in the biopharmaceutical industry. Shareholders also reappointed five board members to varying term lengths, ensuring stability in governance.

Detailed voting results will soon be available on Valneva’s corporate website. These changes highlight Valneva’s strategic focus on long-term value creation for shareholders.